Neuroprotective effect of trans-cinnamaldehyde on the 6-hydroxydopamine- induced dopaminergic injury

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 12, 2013, Pages 1928-1935

  Pyo, Ji Hi ^a   Jeong, You Kyung ^a   Yeo, Sujung ^a   Lee, Je Hyun ^b   Jeong, Mi Young ^a   Kim, Sung Hoon ^a   Choi, Yeong Gon ^a   Lim, Sabina ^a  

^a Kyung Hee University   (South Korea)

^b Dongguk University   (South Korea)

Author keywords

6 hydroxydopamine; Dopaminergic dysfunction; Neurodegeneration; Parkinson's disease; Trans cinnamaldehyde

Indexed keywords

CINNAMALDEHYDE; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REGULATION; INFLAMMATORY CELL; MALE; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; UPREGULATION;

ACROLEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELL SURVIVAL; CORPUS STRIATUM; CYCLOOXYGENASE 2; DOPAMINERGIC NEURONS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDOPAMINE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84892575342     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00537     Document Type: Article

References (55)

1. Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp. Mol. Med., 38, 333-347 (2006).
2. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N.Y. Acad. Sci., 991, 120-131 (2003).
3. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol., 53 (Suppl. , S49-S58, discussion, S58-S60 (2003).
4. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord., 10 (Suppl. , S3-S7 (2004).
5. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, Laurie C, Gendelman HE. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin. Neurosci. Res., 6, 261-281 (2006).
6. Ferrari CC, Tarelli R. Parkinson's disease and systemic inflammation. Parkinsons Dis., 2011, 436813 (2011).
7. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol., 45, 19-34 (1987).
8. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci., 22, 123-144 (1999).
9. Shiraishi Y. Illustrated explanation of Shang Han Lun. Tani-Guchi Shoten, Tokyo (1996).
10. Park HJ, Lee JS, Lee JD, Kim NJ, Pyo JH, Kang JM, Choe IH, Kim SY, Shim BS, Lee JH, Lim S. The anti-inflammatory effect of Cinnamomi Ramulus. J. Korean Oriental Med., 26, 140-151 (2005).
11. Hwang SH, Choi YG, Jeong MY, Hong YM, Lee JH, Lim S. Microarray analysis of gene expression profile by treatment of Cinnamomi Ramulus in lipopolysaccharide-stimulated BV-2 cells. Gene, 443, 83-90 (2009).
12. Lee HS, Kim BS, Kim MK. Suppression effect of Cinnamomum cassia bark-derived component on nitric oxide synthase. J. Agric. Food Chem., 50, 7700-7703 (2002).
13. Reddy AM, Seo JH, Ryu SY, Kim YS, Kim YS, Min KR, Kim Y. Cinnamaldehyde and 2-methoxycinnamaldehyde as NF-kappaB inhibitors from Cinnamomum cassia. Planta Med., 70, 823-827 (2004).
14. Guo JY, Huo HR, Zhao BS, Liu HB, Li LF, Ma YY, Guo SY, Jiang TL. Cinnamaldehyde reduces IL-1beta-induced cyclooxygenase-2 activity in rat cerebral microvascular endothelial cells. Eur. J. Pharmacol., 537, 174-180 (2006).
15. Kim DH, Kim CH, Kim MS, Kim JY, Jung KJ, Chung JH, An WG, Lee JW, Yu BP, Chung HY. Suppression of age-related inflammatory NF-κB activation by cinnamaldehyde. Biogerontology, 8, 545-554 (2007).
16. Chao LK, Hua KF, Hsu HY, Cheng SS, Lin IF, Chen CJ, Chen ST, Chang ST. Cinnamaldehyde inhibits pro-inflammatory cytokines secretion from monocytes/macrophages through suppression of intracellular signaling. Food Chem. Toxicol., 46, 220-231 (2008).
17. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci., 19, 312-318 (1996).
18. Kim BH, Lee YG, Lee J, Lee JY, Cho JY. Regulatory effect of cinnamaldehyde on monocyte/macrophage-mediated inflammatory responses. Mediators Inflamm., 2010, 1-9 (2010).
19. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res., 318, 215-224 (2004).
20. Ahmad S, Khan MB, Hoda MN, Bhatia K, Haque R, Fazili IS, Jamal A, Khan JS, Katare DP. Neuroprotective effect of sesame seed oil in 6-hydroxydopamine induced neurotoxicity in mice model: cellular, biochemical and neurochemical evidence. Neurochem. Res., 37, 516-526 (2012).
21. Rodríguez M, Barroso-Chinea P, Abdala P, Obeso J, Gonzalez-Hernandez T. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson's disease. Exp. Neurol., 169, 163-181 (2001).
22. Khan MM, Ahmad A, Ishrat T, Khan MB, Hoda MN, Khuwaja G, Raza SS, Khan A, Javed H, Vaibhav K, Islam F. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res., 1328, 139-151 (2010).
23. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience, 110, 49-58 (2002).
24. Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. N.Y. Acad. Sci., 962, 318-331 (2002).
25. Liu Y, Qin L, Li G, Zhang W, An L, Liu B, Hong JS. Dextromethorphan protects dopaminergic neurons against inflammationmediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther., 305, 212-218 (2003).
26. Dawson VL, Dawson TM. Nitric oxide in neurodegeneration. Prog. Brain Res., 118, 215-229 (1998).
27. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol., 27, 325-355 (2003).
28. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol., 150, 963-976 (2007).
29. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br. J. Pharmacol., 147 (Suppl. , S232-S240 (2006).
30. Hoozemans JJ, Veerhuis R, Janssen I, van Elk EJ, Rozemuller AJ, Eikelenboom P. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res., 951, 218-226 (2002).
31. Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS-a dual role? Exp. Neurol., 187, 1-10 (2004).
32. Mancuso C, Scapagini G, Currò D, Giuffrida Stella AM, De Marco C, Butterfield DA, Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci., 12, 1107-1123 (2007).
33. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U.S.A., 100, 5473-5478 (2003).
34. Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation, 3, 6 (2006).
35. Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem., 71, 1635-1642 (1998).
36. Scali C, Prosperi C, Vannucchi MG, Pepeu G, Casamenti F. Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication for Alzheimer's disease. Eur. J. Neurosci., 12, 1900-1912 (2000).
37. Mohanakumar KP, Muralikrishnan D, Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-inuced neurotoxicity. Brain Res., 864, 281-290 (2000).
38. Kurkowska-Jastrzȩbska I, Babiuch M, Joniec I, Przybyłkowski A, Członkowski A, Członkowska A. Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int. Immunopharmacol., 2, 1213-1218 (2002).
39. Huss U, Ringbom T, Perera P, Bohlin L, Vasänge M. Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay. J. Nat. Prod., 65, 1517-1521 (2002).
40. Im HI, Joo WS, Nam E, Lee ES, Hwang YJ, Kim YS. Baicalein prevents 6-hydroxydopamine-induced dopaminergic dysfunction and lipid peroxidation in mice. J. Pharmacol. Sci., 98, 185-189 (2005).
41. Ferro MM, Angelucci ME, Anselmo-Franci JA, Canteras NS, Da Cunha C. Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease. Braz. J. Med. Biol. Res., 40, 89-96 (2007).
42. Haavik J, Toska K. Tyrosine hydroxylase and Parkinson's disease. Mol. Neurobiol., 16, 285-309 (1998).
43. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res., 909, 187-193 (2001).
44. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci., 15, 991-998 (2002).
45. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR. Role of nitric oxide synthases in Parkinson's Disease: a review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem. Res., 33, 2416-2426 (2008).
46. Gomes MZ, Raisman-Vozari R, Del Bel EA. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res., 1203, 160-169 (2008).
47. Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci., 16, 724-739 (2000).
48. Saha RN, Pahan K. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid. Redox Signal., 8, 929-947 (2006).
49. Nissbrandt H, Sundström E, Jonsson G, Hjorth S, Carlsson A. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum. J. Neurochem., 52, 1170-1182 (1989).
50. Chen H, Jing FC, Li CL, Tu PF, Zheng QS, Wang ZH. Echinacoside prevents the striatal extracellular levels of monoamine neurotransmitters from diminution in 6-hydroxydopamine lesion rats. J. Ethnopharmacol., 114, 285-289 (2007).
51. Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J. Neurochem., 58, 642-648 (1992).
52. Wang Q, Wang PH, McLachlan C, Wong PT. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res., 1045, 229-233 (2005).
53. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem., 100, 1375-1386 (2007).
54. Hwang H, Jeon H, Ock J, Hong SH, Han YM, Kwon BM, Lee WH, Lee MS, Suk K. 2 -Hydroxycinnamaldehyde targets low-density lipoprotein receptor-related protein-1 to inhibit lipopolysaccharideinduced microglial activation. J. Neuroimmunol., 230, 52-64 (2011).
55. Ahn KS, Aggarwal BB. Transcription factor NF-κB: a sensor for smoke and stress signals. Ann. N.Y. Acad. Sci., 1056, 218-233 (2005).